Skip to main content
All lobbying filings

Twenty-First Century Group, Inc.

Twenty-First Century Group, Inc. filed a Q2 report for NRX Pharmaceuticals Inc. (Formerly Known as Neurorx) on July 20, 2026, reporting $24,000 in lobbying income.

Lobbying for NRX Pharmaceuticals Inc. (Formerly Known as Neurorx) · Pharmaceutical company

As filed: TWENTY-FIRST CENTURY GROUP, INC. for NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX).

All filings by Twenty-First Century Group, Inc. · Everything NRX Pharmaceuticals Inc. (Formerly Known as Neurorx) has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$24,000
What the client paid this registrant for the period.
Client based in
Delaware

Official filing document

 Lobbyists on this filing 2
  • JACK FIELDS Former member of Congress
    Previously held: Former Member of Congress
  • LISA D RULLI
    Previously held: Former staffer, Committee on Merchant Marine & Fisheries; Natural Resources

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.

Medical/Disease Research/Clinical Labs

Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.

Veterans

Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.

Budget/Appropriations

Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD within HR 8646, Fiscal Year 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Bill; ALS research and treatment related to HR 9495, Fiscal Year 2027 Defense Appropriations Bill.

 Bills named in this filing 3
  • H.R. 8205
    Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
  • H.R. 8646
    Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
  • H.R. 9495
    Department of Defense Appropriations Act, 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem